Chromosome translocations involving one donor chromosome and multiple recipient chromosomes have been referred to as jumping translocations (JTs). Acquired JTs are commonly observed in cancer patients, mainly involving chromosome 1. Constitutional forms of JTs mostly involve the acrocentric chromosomes and their satellites and have been reported in patients with clinical abnormalities. Recognizable phenotypes resulting from these events have included Down, Prader-Willi, and DiGeorge syndromes. The presence of JTs in spontaneous abortions has not been previously described. The breakpoints of all JTs occur in areas rich in repetitive DNA (telomeric, centromeric, and nucleolus organizing regions). We report two different unstable chromosome rearrangements in samples derived from spontaneous abortions. The first case involved a chromosome 15 donor. The recipient chromosomes were 1, 9, 15, and 21, and the respective breakpoints were in either the heterochromatic regions or the centromeres. FISH studies confirmed that the breakpoints of the jumping 15 rearrangement did not involve the Prader-Willi region but originated at the centromere or in the proximal short arm. A second case of instability was observed with a rearrangement resulting from a presumed de novo 8;21 translocation. Three JT cell lines were observed. They consisted of a deleted 8p chromosome, a dicentric 8;21 translocation, and an 8q isochromosome. The instability regions appeared to be at the pericentromeric region of chromosome 8 and the satellite region of chromosome 21. Both cases proved to be de novo events. The unstable nature of the JT resulting in chromosomal imbalance most likely contributed to the fetal loss. It appears that JT events may predispose to chromosomal imbalance via nondisjunction and chromosomal rearrangement and, therefore, may be an unrecognized cause of fetal loss.   

Ben-Neriah S, Abramov A, Lerer I, Polliack A, Leizerowitz R, Rabinowitz R, Abeliovich D: “Jumping translocation” in a 17-month-old child with mixed-lineage leukemia. Cancer Genet Cytogenet 56:223–229 (1991).
Brown MG, Lawce HJ: Peripheral blood cytogenetic methods, in Barch MJ, Knutsen T, Spurbeck JL (eds): The AGT Cytogenetics Laboratory Manual, pp 77–171 (Lippincott-Raven, New York 1997).
Cuthbert G, McCullough S, Finney R, Breese G, Bown N: Jumping translocation at 11q23 with MLL gene rearrangement and interstitial telomeric sequences. Genes Chrom Cancer 24:295–298 (1999).
Delhanty JD, Harper JC, Ao A, Handyside AH, Winston RM: Multicolour FISH detects frequent chromosomal mosaicism and chaotic division in normal preimplantation embryos from fertile patients. Hum Genet 99:755–760 (1997).
Devriendt K, Petit P, Matthijs G, Vermeesch JR, Holvoet M, De Muelenaere A, Marynen P, Cassiman JJ, Fryns JP: Trisomy 15 rescue with jumping translocation of distal 15q in Prader-Willi syndrome. J med Genet 34:395–399 (1997).
Drake VJ, Tunnell S, Ward BE, Robinson A: Unbalanced, unstable translocation of 22q. Am J hum Genet 37S:91 (1985).
Duval E, van den Enden A, Vanhaesebrouck P, Speleman F: Jumping translocation in a newborn boy with dup(4q) and severe hydrops fetalis. Am J med Genet 52:214–217 (1994).
Eiben B, Bartels I, Bahr-Porsch S, Borgmann S, Gatz G, Gellert G, Goebel R, Hammans W, Hentemann M, Osmers R, Rauskolb R, Hansmann I: Cytogenetic analysis of 750 spontaneous abortions with the direct-preparation method of chorionic villi and its implications for studying genetic causes of pregnancy wastage. Am J hum Genet 47:656–663 (1990).
Farrell SA, Winsor EJ, Markovic VD: Moving satellites and unstable chromosome translocations: clinical and cytogenetic implications. Am J med Genet 46:715–720 (1993).
Fitzgerald PH, Morris CM: Telomeric association of chromosomes in B-cell lymphoid leukemia. Hum Genet 67:385–390 (1984).
Florijn RJ, Slats J, Tanke HJ, Raap AK: Analysis of antifading reagents for fluorescence microscopy. Cytometry 19:177–182 (1995).
Gardner RJM, Sutherland GR: Chromosome Abnormalities and Genetic Counseling, 2nd Ed (Oxford University Press, New York 1996).
Gross SJ, Tharapel AT, Phillips OP, Shulman LP, Pivnick EK, Park VM: A jumping Robertsonian translocation: a molecular and cytogenetic study. Hum Genet 98:291–296 (1996).
Hatakeyama S, Fujita K, Mori H, Omine M, Ishikawa F: Shortened telomeres involved in a case with a jumping translocation at 1q21. Blood 91:1514–1519 (1998).
Hoffschir F, Ricoul M, Lemieux N, Estrade S, Cassingena R, Dutrillaux B: Jumping translocations originate clonal rearrangements in SV40-transformed human fibroblasts. Int J Cancer 52:130–136 (1992).
Jewett T, Marnane D, Stewart W, Hayworth-Hodge R, Finklea L, Klinepeter K, Rao PN, Pettenati MJ: Jumping translocation with partial duplications and triplications of chromosomes 7 and 15. Clin Genet 53:415–420 (1998).
Kazmierczak B, Stern C, Bartnitzke S, Bullerdiek J: Non-random jumping translocations as a result of SV40 large T-antigen expression in benign human tumor cells. Cell Biol Int 19:315–322 (1995).
Ketterer DM, Casey J, Word A, Sawalqah H, Giles HR: A partially deleted #22 translocated to a #12 and a #19 in a newborn. Am J hum Genet 36S:99 (1984).
Lejeune J, Maunoury C, Prieur M, Van den Akker J: Translocation sauteuse (5p;15q), (8q;15q), (12q;15q) [A jumping translocation (5p;15q), (8q;15q), and (12q;15q)]. Annls Génét 22:210–213 (1979).
Munne S, Lee A, Rosenwaks Z, Grifo J, Cohen J: Diagnosis of major chromosome aneuploidies in human preimplantation embryos. Hum Reprod 8:2185–2191 (1993).
Najfeld V, Hauschildt B, Scalise A, Gattani A, Patel R, Ambinder EP, Silverman LR: Jumping translocations in leukemia. Leukemia 9:634–639 (1995).
Park VM, Gustashaw KM, Wathen TM: The presence of interstitial telomeric sequences in constitutional chromosome abnormalities. Am J hum Genet 50:914–923 (1992).
Petit P, Devriendt K, Vermeesch JR, De Cock P, Fryns JP: Unusual de novo t(13;15)(q12.1;p13) translocation leading to complex mosaicism including jumping translocation. Annls Génét 41:22–26 (1998).
Priest JH: General Cell Culture Principles and Fibroblast Culture, in Barch MJ, Knutsen T, Spurbeck JL (eds): The AGT Cytogenetics Laboratory Manual, pp 172–197 (Lippincott-Raven, New York 1997).
Rossi E, Floridia G, Casali M, Danesino C, Chiumello G, Bernardi F, Magnani I, Papi L, Mura M, Zuffardi O: Types, stability, and phenotypic consequences of chromosome rearrangements leading to interstitial telomeric sequences. J med Genet 30:926–931 (1993).
Sawyer JR, Tricot G, Mattox S, Jagannath S, Barlogie B: Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood 91:1732–1741 (1998).
Seghezzi L, Addis P, Giglio S, Invernizzi R, Maserati E: Jumping translocations in acute lymphoblastic leukemia. Cancer Genet Cytogenet 80:80–81 (1995).
Shikano T, Arioka H, Kobayashi R, Naito H, Ishikawa Y: Jumping translocations of 1q in Burkitt lymphoma and acute nonlymphocytic leukemia. Cancer Genet Cytogenet 71:22–26 (1993).
Shippey CA, Layton M, Secker-Walker LM: Leukemia characterized by multiple sub-clones with unbalanced translocations involving different telomeric segments: case report and review of the literature. Genes Chrom Cancer 2:14–17 (1990).
Vermeesch JR, Petit P, Speleman F, Devriendt K, Fryns JP, Marynen P: Interstitial telomeric sequences at the junction site of a jumping translocation. Hum Genet 99:735–737 (1997).
Yoshida T, Kimura N, Akiyoshi T, Ohshima K, Nagano M, Morioka E, Hisano S, Ohyashiki K, Kamada N, Tamura K: Jumping translocation of homogeneously staining region and tetraploidy with double minutes in acute myelomonocytic leukemia. Cancer Genet Cytogenet 109:40–44 (1999).
Zellweger H, Abbo G: Familial mosaicism attributable to a new gene. Lancet i:455–457 (1965).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.